LIVE POLIO IRUS VACCINES

622 Index
Monkey neurovirulence, 95, 124
and lab manipulation, 127
base line for Lederle vaccine, 31-32, 37
comparison of Murray's and Cabasso's findings, 77
comparison of vaccine strains, 31, 90-93, 96
definition, 6
enhancement of virulence, 16, 143
formula for evaluation, 32
increase, Type 3 vaccine, 49
intracerebral and intraspinal inoculation, differences,
46, 70
intracerebral inoculation right thalamic region, 137
intramuscular inoculation, 90-97
of Type 1 isolate, 540
Monkey non-neurovirulent virus
isolated from paralytic patient, detail request, 202
Monterrey, Mexico
vaccination program, 1958, 386
Montoya, Juan A., paper 561-573; 113, 184
Moorestown, N.J.
Type 1 polio isolated, 54
Morales, Mary, 118
Morbidity, see also Susceptibility
analysis of epidemiological effectiveness, 487
rates
Czechoslovakia, 509-510
Netherlands, 135-138
Russia, 493
reduction in Baltic, 586
related to seroimmunity and spread, 520
Morgan City, Louisiana
homogeneous play community, 145
map, 146
Mortality
data in Salk vaccinated, 435
in mothers and newborn, 326
rate, Nicaragua, 547-548
Moscow, 582
incidence of vaccinated and unvaccinated, 421
laboratory diagnoses substantiated, 420
public health service, adequacy, 577
Sabin vaccine tested, 580
Moscow region, 240, 242, 246, 249
Moscow regional hospital
multiplication studied in poliomyelitis convalescents,
240
Moses, Max J., paper 330-340
Mothers
5% carriers of polio, Toluca, Mexico, 410
Mouse mammary carcinoma "milk agent"
limited to certain breeds, 329
Moyer, Arden W., paper 31-37, 330-340; 98
MS marker
and covariation, 49
change from MS- to MS+ in Type 3 vaccine, 197
compared with temperature markers, 58
criteria for vaccine, 31
differential growth on stable-line cells and MK
culture, 7
for identification of isolates, 199, 469
relation to Lederle-Cox vaccine, 33
unchanged with variation of d or t, 34
value not definitely established, 37
Miller, P., 322
Mumps
and polio vaccination, 368
Murray, Roderick, paper 90-97, 124-131; 77, 87-88,
373, 439, 463, 574
Murray technique, 68
Mutation, see also Cold mutants
and strain identification, 480
gene situation and covariation, 49
may involve marker, 47
rate, 110
Mycostatin
in stool suspensions, 536
Myxovirus parainfluenza 1 and 3
vacuolating virus recovered from seed stocks, 80
Na + cation
active factor in d marker, 45
Nagaoka, Niigata prefecture, Japan
epidemics, 199
field trial, 193
Nairobi, Kenya
1,500,000 vaccinated, 479
Nathanson, N., 94, 100
National Foundation, The
Salk vaccine information, 419
National Institutes of Health, Bethesda, Maryland,
98, 439, 463
Needle tract
inflammatory reaction in the anterior horn, 73
Netherlands, 520
field trial, 134-142
incidence, 429
map of study areas, 136
regions listed, 134
Sabin vaccine test, 580
Neuron receptor substance
property of combination, 49
Neuronal damage
grading system, 91
Neurotropic virus
mouse as natural bost, 39
Neurovirulence
cold-mutant capacity and, 36, 67, 105, 107, 125
correlation with man, 12, 190
degree, with diphtheria complication, 197
epidemiological significance, monkeys, 600
increase during serial passage in children, 414, 485
not increased during passage, 505
relation to markers, 12-25, 31-37, 38, 47, 118, 140-
141
safety, 144, 192
sampling failure and passages, 50
tissue culture passage and reversion, 49
Neutralization tests
and measurement of antibodies, 228-239
for an interfering virus, 203
isolates of vacuolating agent were identified, 80
technique and results, 229, 266, 271, 486, 536
Newborns, see also Infants
antibody levels, 6, 217, 329
compared with 3-month-old infants, 302
conversion rates, 568